T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoom
ZM
|
+$3.3B |
| 2 |
Eli Lilly
LLY
|
+$2.75B |
| 3 |
AstraZeneca
AZN
|
+$1.98B |
| 4 |
Coupang
CPNG
|
+$1.54B |
| 5 |
Fortinet
FTNT
|
+$1.48B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NXP Semiconductors
NXPI
|
+$2.34B |
| 2 |
Morgan Stanley
MS
|
+$2.26B |
| 3 |
Airbnb
ABNB
|
+$2.04B |
| 4 |
Qualcomm
QCOM
|
+$1.95B |
| 5 |
NVIDIA
NVDA
|
+$1.81B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.35% |
| 2 | Healthcare | 16.19% |
| 3 | Consumer Discretionary | 15.55% |
| 4 | Financials | 12.84% |
| 5 | Communication Services | 12.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
HNGR
776
DELISTED
Hanger Inc.
HNGR
| $101M | 0.01% |
4,433,439
+29,836
| +0.7% | +$683K |
|
777
Enbridge
ENB
$112B
| $101M | 0.01% |
2,770,149
-4,046,773
| -59% | -$142M |
|
|
FBMS
778
DELISTED
The First Bancshares, Inc.
FBMS
| $100M | 0.01% |
2,738,965
+2,903
| +0.1% | +$97.4K |
|
779
Deckers Outdoor
DECK
$12.7B
| $100M | 0.01% |
1,819,122
+200,244
| +12% | +$10.7M |
|
780
Heritage Financial
HFWA
$1.23B
| $99.4M | 0.01% |
3,521,245
-55,814
| -2% | -$1.46M |
|
781
Takeda Pharmaceutical
TAK
$55.5B
| $99.3M | 0.01% |
5,436,898
+74,254
| +1% | +$1.34M |
|
|
HZNP
782
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $99.1M | 0.01% |
1,076,703
-89,343
| -8% | -$7.54M |
|
783
Advantage Solutions
ADV
$423M
| $99.1M | 0.01% |
335,567
+55,040
| +20% | +$14.7M |
|
784
Occidental Petroleum
OXY
$57.7B
| $98.8M | 0.01% |
3,709,900
-111,002
| -3% | -$2.78M |
|
785
Helen of Troy
HELE
$699M
| $98M | 0.01% |
465,134
-37,373
| -7% | -$8.43M |
|
786
Exponent
EXPO
$3.24B
| $97.9M | 0.01% |
1,005,113
-68,593
| -6% | -$6.44M |
|
|
NVTA
787
DELISTED
Invitae Corporation
NVTA
| $96.7M | 0.01% |
2,531,776
+419,051
| +20% | +$19M |
|
788
Mohawk Industries
MHK
$9.42B
| $96.7M | 0.01% |
502,964
-3,440
| -0.7% | -$573K |
|
789
MaxLinear
MXL
$6.95B
| $96.6M | 0.01% |
2,835,125
-542,648
| -16% | -$19.4M |
|
790
Tandem Diabetes Care
TNDM
$1.61B
| $96.6M | 0.01% |
1,094,315
-277,065
| -20% | -$25.7M |
|
791
KT
KT
$9.03B
| $96.4M | 0.01% |
7,749,895
+45,000
| +0.6% | +$510K |
|
792
Cedar Fair
FUN
$1.71B
| $96.2M | 0.01% |
1,936,261
+212,277
| +12% | +$9.67M |
|
793
Nurix Therapeutics
NRIX
$2.82B
| $96.2M | 0.01% |
3,093,705
+2,502,069
| +423% | +$94.7M |
|
|
CKH
794
DELISTED
Seacor Holdings Inc.
CKH
| $95.4M | 0.01% |
2,340,576
-643,339
| -22% | -$26.9M |
|
795
Parsons
PSN
$5.08B
| $95.2M | 0.01% |
2,355,173
+90,602
| +4% | +$3.43M |
|
|
NUVA
796
DELISTED
NuVasive, Inc.
NUVA
| $95M | 0.01% |
1,449,218
-45,316
| -3% | -$2.72M |
|
797
Houlihan Lokey
HLI
$9.24B
| $95M | 0.01% |
1,428,042
+2,181
| +0.2% | +$147K |
|
798
Kilroy Realty
KRC
$4.3B
| $94.5M | 0.01% |
1,439,582
+378,827
| +36% | +$23.4M |
|
799
Replimune Group
REPL
$1.42B
| $93.9M | 0.01% |
3,078,242
+452,551
| +17% | +$16.9M |
|
800
Gold Fields
GFI
$35.4B
| $93.2M | 0.01% |
9,825,761
+1,365,199
| +16% | +$12.7M |
|
Similar funds
T. Rowe Price Associates's Q1 2021 Portfolio in Review
As of Q1 2021, T. Rowe Price Associates held 2,908 positions worth $999B, up 2.5% from $974B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
T. Rowe Price Associates's Q1 2021 filing shows 248 new, 1,171 increased, 1,334 reduced and 66 closed positions. Its largest new stake was Coupang: 33,380,859 shares worth $1.63B. The largest sale was NXP Semiconductors, an estimated $2.34B.
By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q1 2021 buy was Coupang: 33,380,859 shares worth $1.63B.
- T. Rowe Price Associates added most to Zoom in Q1 2021, an estimated $3.3B increase.
- T. Rowe Price Associates's biggest Q1 2021 reduction was NXP Semiconductors, cutting an estimated $2.34B.
- T. Rowe Price Associates fully exited CONCHO RESOURCES INC. in Q1 2021, selling an estimated $205M.
- T. Rowe Price Associates's ten largest holdings make up 24% of its $999B portfolio in Q1 2021.
- T. Rowe Price Associates opened 248 new positions and closed 66 in Q1 2021.
- T. Rowe Price Associates's portfolio value rose 2.5% quarter-over-quarter to $999B.
Based on T. Rowe Price Associates's 13F filing for Q1 2021, filed 17 May 2021.